pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Type 2 Diabetes · news · pharmadog
← back to Type 2 Diabetes
News mentioning Type 2 Diabetes
86
stories
3d
STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more
stat
3d
#EASD26: Boehringer's weight loss candidate trails rivals in diabetes and obesity
endpoints
3d
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
fiercebiotech
4d
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
4d
#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
endpoints
4d
STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
stat
4d
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
4d
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
4d
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program
fiercebiotech
4d
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
fiercebiotech
5d
#EASD26: Lilly's triple-G allows 60% of patients to drop below obesity threshold
endpoints
5d
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
5d
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
5d
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
9d
STAT+: Lilly wins approval for once-weekly insulin shot
stat
9d
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
biopharma dive
9d
Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
fiercebiotech
10d
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
fiercebiotech
10d
FDA approves Eli Lilly's once-weekly insulin pen, setting up rivalry with Novo
endpoints
10d
Lilly’s latest China drug deal; Immunovant’s setback in lupus
biopharma dive
10d
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
biospace
11d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
12d
Vertex opens up larger kidney disease opportunity with mid-stage readout
biospace
12d
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
12d
STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program
stat
12d
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
biospace
12d
Roche reports Phase 2 enicepatide data in overweight or obese patients with diabetes
endpoints
12d
Vertex’s midstage data amplify kidney disease market opportunity
fiercebiotech
12d
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
fiercebiotech
13d
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
← prev
page 1 of 3
next →
